Table 3.
Effect of Diabegon® on blood cholesterol, triglyceride & HDL-C in MetS with Non-insulin dependent diabetes mellitus subjects of different age groups (N=58)
| (Group) | Total Cholesterol (mg/dl) | Triglyceride (mg/dl) | HDL-C (mg/dl) | |||||||||
| Initial (a) | 6 month of therapy (b) |
12 month of therapy(c) |
18 month of therapy (d) |
Initial (a) | 6 month of therapy (b) |
12 month of therapy(c) |
18 month of therapy (d) |
Initial (a) | 6 month of therapy (b) |
12 month of therapy(c) |
18 month of therapy (d) |
|
| Group I (35–50) ,N=10 |
197.9±19.2 | 161.7±47.8 a* |
139.9±31.4 a** |
147.1±17.6 a** |
281.4±93.9 | 192.5±31 a* |
110.06±8.8 a**b** |
126.3±37.8 a**b** |
27.9±1.43 | 36.7±5.3 a** |
39.5±16.7 | 54.5±23 a*b* |
| Group II (51–65), N=34 |
167.4±20.1 | 183.5±42.1 a* |
153.5±23.2 a*b** |
148.9±44.8 a*b* |
169.3±29.4 | 120.3±56.7 a** |
121±16 a** |
111.7±47.6 a** |
44±10.4 | 32.2±5.8 a** |
42.2±21.5 b* |
51.9±15 a*b** |
| Group III >65, N=14 |
176.7±10.6 | 163.3±65.8 | 163.1±17.8 | 151±43 \a* | 133.5±33.4 | 157.4±14.4 a* |
136.8±43.4 | 101.2±30 a*b**c* |
40.7±11.6 | 41.7±8.1 | 40.95±5.9 | 51.2±25 |
| CB-IV, N=43 FBS<145.9 |
158.9±18.3 | 166.7±50.4 | 156±57.7 | 144.7±39.4 a*b* |
158±80.6 | 131.8±49.6 | 114.6±50.9 a* |
114±59 a* |
41.4±13.3 | 35.2±6.2 a* |
40.5±16.9 | 52.7±19.3 a**b**c** |
| CB-V, N=15 FBS<145.9 |
204.3±16.3 | 168.2±19.9 a** |
145.7±35.2 a**b* |
148.6±11.8 a**b* |
195.2±41.2 | 131.7±16.6 a** |
118.2±27.1 a** |
123.1±28.9 a** |
33.5±4.1 | 42.8±10.3 a* |
41.9±19.5 | 52±30 a* |